Background: MYBPC3 mutations have been described in dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). A mutation, c.3373G>A, has been reported to cause autosomal recessive form of HCM. Here, we report that this mutation can cause autosomal dominant form of DCM.
Methods: Next-generation sequencing using targeted panel of a total of 23 candidate genes and following Sanger sequencing was applied to detect causal mutations of DCM. Computational analyses were also performed using available software tools.
In silico structural and functional analyses including protein modeling and prediction were done for the mutated MYBPC3 protein.
Results and Conclusion:
Targeted sequencing showed one variant c.3373G>A
(p.Val1125Met) in the studied family following autosomal dominant inheritance.
Computational programs predicted a high score of pathogenicity. Secondary structure of the region surrounding p.Val1125 was changed to a shortened beta-strand based on prediction of I-TASSER and Phyre2 servers with high confidence value for the mutation. cMyBP-C protein was modeled to 3dmkA. Our findings suggest that one single mutation of MYBPC3 may have different effects on the cellular mechanisms based of its zygosity. Various factors might be considered for explaining this phenomenon. This gene may have an important role in Iranian DCM and HCM patients.
K E Y W O R D S
dilated cardiomyopathy, hypertrophic cardiomyopathy, Iranian population, MYBPC3, p.Val1125Met DCM as one of the leading causes of sudden cardiac death is a predominant form of inherited cardiac disease in humans, estimated to be 1 in 2500 individuals in general population. 10 It is characterized by the enlargement of cardiac ventricular chamber and systolic dysfunction.
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The prevalence of DCM has not been reported yet in
Iran. The majority of DCM patients are sporadic; however, familial DCM has been determined in 20%-35% of the patients. 11 Familial DCM is usually inherited as autosomal dominant, [12] [13] [14] although, autosomal recessive, X-linked, or mitochondrial inheritance patterns are observed in a small number of cases [15] [16] [17] [18] reflecting a wide locus heterogeneity for its etiology. Currently, more than 50 genes, which encode cytoskeletal, mitochondrial, nucleoskeletal, and calciumhandling proteins, have been documented to cause DCM. 15, 19 Reduced penetrance and phenotypic variability phenomena have also been reported in DCM. 19 Locus heterogeneity and allelic disorders may also complicate this scenario; that is, the type of gene and mutation often leads to difference in the clinical features, age of onset, and prognosis of DCM.
Targeted next-generation sequencing may be the best option to detect disease-causing variants of the reported genes involved in heterogeneous disorders such as cardiomyopathies. Here, a heterozygous missense mutation in MYBPC3 gene, which has been previously described to cause HCM in its autosomal recessive form, is reported in a woman affected with DCM for the first time. In addition, computational analyses including protein modeling and prediction of pathogenicity are also presented.
| MATERIAL S AND ME THODS

| Clinical evaluations
A woman with frequent palpitations and dyspnea was referred to Echocardiography Laboratory of Rajaee Heart Hospital. F I G U R E 1 Schematic representation of cMyBP-C protein structure. cMyBP-C is a multi-modular protein composed of 8 immunoglobulinlike (C0, C1, C2, C3, C4, C5, C8, C10) and 3 fibronectin type III (C6, C7, C9) domains. The cardiac isoform differs from the slow skeletal and the fast skeletal isoforms by cardiac-specific regions (C0, M, 28-amino acid insertion in C5). Between C0 and C1 exists a proline-alanine rich domain (Pro-Ala; PA). The location of DCM associated mutation identified in our study is shown above the C9 domain. The C9 contributed interactions have indicated as well F I G U R E 2 A, Multiple amino acid alignment of cMyBP-C protein adapted from UniProt protein family members. p.Val1125 as indicated in the box shows high conservation among different species. B, Cartoon structural model of human cMyBP-C protein constructed by I-TASSER based on 3dmkA (Down syndrome cell adhesion molecule (DSCAM) isoform 1.30.30, N-terminal eight Ig domains) with a Normalized Z-score >1 equal to 2.56; alignment with a Normalized Z-score >1 mean a good alignment and vice versa. Structure prediction of cMyBP-C protein was based on I-TASSER server. The position of residue 1125 is shown in larger resolution in 3D structure. The schematic structures of the original (left) and the mutant (right) amino acid are also shown. C, Predicted secondary structure based on threading model by I-TASSER, first line indicates the sequence, second line indicates the secondary structure, which is determined to be strand at position 1125 with the confidence score of 9 (third line). The range of confidence is 0-9 wherein a higher score indicates a prediction with higher confidence. The solvent accessibility of the sequence is predicted as buried amino acid (range 0-9 wherein a higher value means higher accessibility). D) Prediction of the secondary structure based on template/homology modeling by Phyre 2 server. First line indicates the amino acid sequence and the second line is the secondary structure prediction, which is determined as beta-strand structure with the confidence value of high score (light red, depicted in line three) in mutated protein (Val1125), also this position is ordered which means it is not flexible and dynamic with high value (light red)
| Mutation screening and in silico analysis
The sequencing was performed using a custom-designed Nimblegen chip capturing coding regions and exon-intron boundaries of 23 candidate genes associated with DCM (Table S1 ). The enrichment was done using NimbleGen kit (NimbleGen, Roche, Basel, Switzerland).
Genomic DNA was sequenced by targeted next-generation sequencing (NGS) on an Illumina, Hiseq2000 (Illumina, San Diego, California, USA). Reads were, then, aligned using Burrows-Wheeler aligner (BWA) on reference genome (hg19). SAMTools was applied for annotation. Filtering was performed based on the mentioned gene panel (Table S1 ). Variants were selected based on their frequency (minor allele frequency <0.1) in 1000 Genome and ExAC.
The coverage of target genes was more than 95%, with sensitivity of more than 99%. Sanger sequencing was performed to confirm mutations. Briefly, the PCR products were sequenced using the BigDye termination method by sequencing analyzer of ABI 3130XL model (PE Applied BioSystems, Massachusetts, USA).
Online software tools and servers were applied to analyze the variants. Sorting intolerant from tolerant (SIFT), 20 polymorphism phenotyping (PolyPhen-2 v2.1), 21 MutationTaster, 22 Combined
Annotation Dependent Depletion (CADD), 23 and PROVEAN (Protein Variation Effect Analyzer) 24 were used to predict the effects of mutation. A multiple sequence alignment of cMyBP-C protein was performed using UniProtKB/Swiss-Prot to check conserved domain among different paralogs and orthologs. The protein sequence of cMyBP-C (UniProtKB/Swiss-Prot Q14896) was compared using protein homology/analogy recognition engine V2.0 (Phyre2) to investigate effects of the variants on the structure and function of protein. 25 In addition, iterative threading assembly refinement (I-TASSER) server was used to predict the structure and function of mutated and normal protein. 26 Modeling was performed using LOMETS threading program. In addition, interaction of cMyBP-C protein was predicted by STRING database (version 10.5), a database for prediction of protein-protein interactions.
The interaction includes physical and functional associations derived from genomic context, high-throughput experiments, coexpression, automated text mining and previous knowledge. on the cMyBP-C protein sequence (Figure 1 ). Subsequent Sanger sequencing confirmed the mutation. The variant was predicted to be damaging using pathogenicity prediction SIFT software (with Median conservation above 3.25). PolyPhen and MutationTaster software tools also predicted the mutation to be probably damaging and disease-causing (Table S2 ).
| Structural and functional analyses of MYBPC3
p.Val1125Met was subjected to sequence alignment among other species for conserved residues and the degree of conservation.
Valine at position 1125 is highly conserved (Figure 2A ). Secondary structure was predicted for p.Val1125Met with available tools.
Protein model prediction using I-TASSER is based on threading model. Secondary structure was predicted to be beta-strand 
| D ISCUSS I ON
MYBPC3 is one of the most common genes involved in HCM; its mutations are observed in about forty percent of the patients. 6 Nevertheless, it has been shown that MYBPC3 mutations can cause various forms of cardiomyopathies such as DCM. Here, an individual affected by DCM is presented due to MYBPC3 mutation. Several studies have reported different mutations of MYBPC3 in DCM and other cardiomyopathies. [28] [29] [30] Missense mutations located in MYBPC3 gene comprise the majority of DCM associated mutations. 31, 32 To our knowledge, it has not been reported that one mutation expresses two different patterns of inheritance.
As known, DCM accounting for about half of all heart transplantations is a major cause of sudden death in young adults. Up to 35% of DCM cases show a familial pattern of inheritance, reflecting a strong genetic influence. 33 In view of this fact, delineation of the genetic basis of DCM contributes to deeper understanding its pathogenesis and it may improve the diagnosis, prevention, and treatment of this disease. In this current study, we surprisingly detected a heterozygous MYBPC3 mutation (p.Val1125Met, rs121909378), in a patient with DCM. This mutation was first reported in a patient with autosomal recessive HCM. 
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